Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[A new reliable model for ischemic colitis: preliminary report].
Ichihara T, Nagahata Y, Ito A, Moritomo H, Kuroda H, Urakawa K, Saitoh Y. Ichihara T, et al. Among authors: kuroda h. Nihon Geka Gakkai Zasshi. 1990 Feb;91(2):295. Nihon Geka Gakkai Zasshi. 1990. PMID: 2325617 Japanese. No abstract available.
The effect of dopamine on rat gastric motility.
Nagahata Y, Urakawa T, Kuroda H, Tomonaga K, Idei H, Kawakita N, Yoshizumi K, Saitoh Y. Nagahata Y, et al. Among authors: kuroda h. Gastroenterol Jpn. 1992 Aug;27(4):482-7. doi: 10.1007/BF02777783. Gastroenterol Jpn. 1992. PMID: 1356091
[Effects of dopamine on stress ulcer].
Nagahata Y, Urakawa T, Moritomo H, Ichihara T, Itoh A, Takeda K, Kuroda H, Idei H, Tomonaga K, Saitoh Y. Nagahata Y, et al. Among authors: kuroda h. Nihon Shokakibyo Gakkai Zasshi. 1990 Jun;87(6):1376-82. Nihon Shokakibyo Gakkai Zasshi. 1990. PMID: 2214262 Japanese.
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.
Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Hirooka M, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T. Naganuma A, et al. Among authors: kuroda h. Cancer Med. 2025 Jan;14(2):e70618. doi: 10.1002/cam4.70618. Cancer Med. 2025. PMID: 39840727
Microwave ablation vs. single-needle radiofrequency ablation for the treatment of HCC up to 4 cm: A randomized-controlled trial.
Sugimoto K, Imajo K, Kuroda H, Murohisa G, Shiozawa K, Sakamaki K, Wada T, Takeuchi H, Endo K, Abe T, Matsui T, Murakami T, Yoneda M, Nakajima A, Kokubu S, Itoi T. Sugimoto K, et al. Among authors: kuroda h. JHEP Rep. 2024 Nov 13;7(1):101269. doi: 10.1016/j.jhepr.2024.101269. eCollection 2025 Jan. JHEP Rep. 2024. PMID: 39802807 Free PMC article.
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798579 Clinical Trial.
1,316 results